We are pleased to announce the 2nd AnnualEuropean Symposium on Lung Cancers™, which will focus on how clinicians can best incorporate new approaches, including personalized medicine, targeted agents, and immunotherapy. While these new approaches hold the promise of improved outcomes for patients with lung cancer, they also lead to increased demand on physicians to understand new paradigms in molecular testing, treatment selection, and management of adverse events with new categories of therapies.
This highly interactive and practical program will include internationally recognized experts in lung cancer describing recent key studies in the field, as well as extensive case-based discussions that go beyond the data in addressing challenges faced in the clinic. This meeting will also enable participants to engage directly with experts and with their peers to share their perspectives, personal experiences, and approaches to optimizing care for their patients with lung cancer.
New for 2018!
We have added several new features to this year’s meeting to enhance the educational and collaborative experience for attendees. A multidisciplinary tumor board will demonstrate cross-disciplinary assessment of patient cases and selection of the optimal therapeutic interventions. A session will also be dedicated to the pulmonologist’s view of lung cancer screening, diagnosis, and multimodality therapy. Finally, an afternoon Poster Walk will allow attendees to share and discuss their clinical research with other investigators in the field.
2018 Featured Topics
State-of-the-art application of immunotherapy in metastatic non-small cell lung cancer (NSCLC)
Emergence of immunotherapy in locally advanced NSCLC
New standards for patients with EGFR-mutated and ALK-rearranged NSCLC, and recent data on therapies to target other oncogenic drivers
Role of liquid biopsies for treatment selection
Pulmonologist’s perspective on best practices in lung cancer diagnosis and therapy
Therapeutic advances in small cell lung cancer (SCLC) and mesothelioma
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, as well as other healthcare professionals involved in the treatment and management of patients with lung cancer.
At the conclusion of this symposium, you should be better prepared to:
Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
Utilize tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced NSCLC
Discuss current and emerging roles for single agent and combination immunotherapeutic strategies in the management of advanced lung cancers
Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
Assess evolving data sets concerning the use of ALK inhibition in front-line and subsequent lines of care in advanced NSCLC
Discuss emerging targeted approaches for oncogenic drivers in NSCLC beyond EGFR and ALK
Identify approaches to address treatment-related toxicities in patients with lung cancer
Integrate personalized approaches to manage challenging cases in advanced lung cancer settings
Benjamin Besse, MD, PhD
Head of Thoracic Tumor board, Department of Medicine
Prof. Dr. med. Martin Reck
Head of the Thoracic Oncology and Clinical Trial Departmentsbr /<> LungenClinic Grosshansdorf
Enriqueta Felip MD, PhD
Director Thoracic and Head and Neck Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Keith Kerr, BSc, MBChB, FRCPath, FRCPE
Honorary Chair in Pulmonary Pathology
Aberdeen University Medical School
Tony Mok, MD
Chairman, Dept. of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China
Noemi Reguart, MD, PhD
Consultant Thoracic Oncology
Medical Oncology Department
Hospital Clinic, IDIBAPS, University of Barcelona